Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.

Authors :: De Cobelli O
Buonerba C
Terracciano D
Bottero D
Lucarelli G
Bove P
Altieri V
Coman I
Perdonà S
Facchini G
Berretta M
Di Lorenzo G
Grieco P
Novellino E
Franco R
Caraglia M
Manini C
Mirone V
De Placido S
Sonpavde G
Ferro M
Source :: Future oncology (London, England) [Future Oncol] 2015 Nov; Vol. 11 (22), pp. 3091-8. Date of Electronic Publication: 2015 Sep 18.
Publication Year :: 2015
Abstract: Aim: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients.<br />Methods: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry.<br />Results: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55-68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23-100.48).<br />Conclusions: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.

Subjects :: Aged
Biopsy
Disease Progression
Humans
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Prostatectomy
Prostatic Neoplasms genetics
Prostatic Neoplasms surgery
Receptors, G-Protein-Coupled genetics
Retrospective Studies
Preoperative Period
Prostatic Neoplasms metabolism
Prostatic Neoplasms pathology
Receptors, G-Protein-Coupled metabolism

Full Text Access

Tools